IPH4502

May 12, 2026 — Innate Pharma (Euronext: IPH; Nasdaq: IPHA) reported a Q1 2026 business update and financial results for the quarter ended March 31, 2026, highlighting progress across its oncology pipeline and a constrained cash runway.

Key pipeline updates: the lacutamab confirmatory Phase 3 TELLOMAK-3 trial in cutaneous T-cell lymphoma (Sézary syndrome and mycosis fungoides) remains planned for H2 2026, contingent on securing non-dilutive financing (e.g., partnering/royalty structures). The FDA previously reviewed the Phase 3 protocol with no further comments (Nov 2025) and granted Breakthrough Therapy Designation for relapsed/refractory Sézary syndrome (Feb 2025). For IPH4502 (Nectin-4 ADC), the maximum tolerated dose has been reached; enrollment in Phase 1 dose escalation/enrichment is nearing completion with preliminary anti-tumor activity (including post–enfortumab vedotin urothelial cancer) and favorable safety to date. AstraZeneca-led PACIFIC-9 (durvalumab ± monalizumab/oleclumab) has completed enrollment with data expected H2 2026. MATISSE Phase 2 (IPH5201 + durvalumab + platinum chemo) interim data in 40 resectable stage II–IIIA NSCLC patients showed pCR 27.5% (95% CI 14.6–43.9), higher in PD-L1–positive tumors; enrollment continues in PD-L1 ≥1%.

Financially, cash and financial assets were €25.4m at March 31, 2026 (runway anticipated to end of Q3 2026); Q1 revenue was €2.6m. The company also completed planned layoffs as part of streamlining.